Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

News
Video

Domenica Lorusso, MD, PhD, presents the final overall survival data from the randomized open -label phase 2 trial of relacorilant, a selective glucocorticoid receptor modulator in combination with nab-paclitaxel versus nab-paclitaxel alone in patients with recurrent platinum resistant ovarian cancer.

Related Videos
Yang Yang Hartwich, PhD
John Paul Diaz, MD
Gottfried Konecny, MD
Keiichi Fujiwara, MD, PhD, Saitama Medical University International Medical Center
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Gottfried Konecny, MD
Ramez N. Eskander, MD
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
Related Content
John Friend, MD

EVT801 Is Well Tolerated, Elicits Disease Control in Advanced Ovarian Cancer

May 1st 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
FDA

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

April 29th 2024
Article
R. Wendel Naumann, MD

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023
Podcast
Sara Corvigno, MD, PhD

Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

April 27th 2024
Article
Shannon N. Westin, MD, MPH, FACOG

DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer

April 26th 2024
Article